Licensing Momentum Leverage Mithra's active licensing track record, including deals with Fuji Pharma for Estelle and related milestone payments, to target regional license partners and co-commercialization opportunities across Europe and beyond.

CDMO Growth Engine Mithra's end-to-end Mithra CDMO platform offers research, development and specialist manufacturing for complex contraception, menopause and hormone-dependent cancers, presenting a compelling value prop to biotech and pharma partners seeking end-to-end outsourcing.

Women’s Health Focus The portfolio centered on estetrol-based contraception and next‑gen hormone therapy Donesta presents a clear entry point for clinics, hospitals and payer networks seeking improved efficacy, safety and convenience in women’s health across life stages.

Global Market Access With a wide geographic footprint and a capable team, Mithra can accelerate regional market entry through local distributors, regulatory collaboration and regional clinical evidence programs to expand adoption of Estelle, Donesta and related therapies.

Pipeline Collaboration Active exploration of CSF-1R inhibitors for endometriosis, oncology and inflammatory disorders signals opportunities for co-development or out-licensing partnerships with pharma players seeking novel women’s health and inflammatory disease assets.